Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • News
    • News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
  • Toggle search form

[Disclosure] Hanwha Aerospace (012450) Reports FY2025 Annual Revenue Exceeds KRW 26.6T, Marking a Significant 136.7% Year-on-Year Growth

Posted on February 9, 2026July 19, 2026 By K-STOCK Editor No Comments on [Disclosure] Hanwha Aerospace (012450) Reports FY2025 Annual Revenue Exceeds KRW 26.6T, Marking a Significant 136.7% Year-on-Year Growth

Source Facts: Financial Supervisory Service Electronic Disclosure System (DART) / 2026-02-09

Disclosure Type: Earnings Release (Preliminary Results) based on Consolidated Financial Statements (Public Disclosure)

💡 3-Second Summary

This disclosure presents Hanwha Aerospace’s preliminary financial results for FY2025, where annual consolidated revenue increased by 136.72% year-on-year to KRW 26.6T and operating profit rose by 75.21% to KRW 3.03T, confirming expansion in both scales.

📊 1. [Summary of Core Disclosure Content and Major Figures]

  • Performance Period:
    • Current Period (Q4 2025): October 1, 2025 – December 31, 2025
    • Cumulative Period (FY2025 Annual): January 1, 2025 – December 31, 2025
  • Details of Preliminary Consolidated Financial Metrics (Unit: KRW 100 Million, %):
    • Sales (Revenue):
      • Q4 2025: KRW 83,261 hundred million (+28.36% QoQ, +72.56% YoY)
      • FY2025 Cumulative: KRW 266,078 hundred million (+136.72% YoY vs. FY2024 cumulative)
    • Operating Profit:
      • Q4 2025: KRW 7,528 hundred million (-12.10% QoQ, -16.33% YoY)
      • FY2025 Cumulative: KRW 30,345 hundred million (+75.21% YoY vs. FY2024 cumulative)
    • Profit Before Income Tax from Continuing Operations:
      • Q4 2025: KRW 6,024 hundred million (-25.81% QoQ, -71.57% YoY)
      • FY2025 Cumulative: KRW 21,450 hundred million (-18.98% YoY vs. FY2024 cumulative)
    • Net Income:
      • Q4 2025: KRW 9,337 hundred million (+31.10% QoQ, -54.65% YoY)
      • FY2025 Cumulative: KRW 21,417 hundred million (-15.68% YoY vs. FY2024 cumulative)
    • Net Income Attributable to Controlling Interests:
      • Q4 2025: KRW 6,155 hundred million (+26.52% QoQ, -66.67% YoY)
      • FY2025 Cumulative: KRW 13,880 hundred million (-39.62% YoY vs. FY2024 cumulative)
  • Information Provision: A conference call for the Q4 2025 earnings release was held on February 9, 2026, at 15:30 for domestic and international investors and the media.
  • Additional Information: These preliminary figures are prepared in accordance with Korean International Financial Reporting Standards (K-IFRS) prior to the completion of the external auditor’s review and are subject to change during the formal audit process.

📈 2. [Expert View: What This Disclosure Means for Investors]

This regulatory filing provides clear quantitative documentation of the company’s financial performance over both the single quarter and the full fiscal year. On a cumulative annual baseline, revenue reached KRW 26,607.8B, marking an increase of 136.72% year-on-year, while annual operating profit expanded by 75.21% to KRW 3,034.5B, confirming top-line expansion across these specific categories. The quarterly progression shows that Q4 revenue rose 28.36% compared to the immediate preceding quarter (Q3 2025).

However, the reported figures also document that annual net income and net income attributable to controlling interests decreased by 15.68% and 39.62% year-on-year respectively. For Q4 2025, operating profit contracted by 12.10% QoQ and 16.33% YoY. Because the source text establishes these metrics as unaudited preliminary data, investors should utilize this disclosure as a conditional guideline, focusing on cross-referencing these numerical trends against the final audited financial statements following formal approval.

📝 Editor’s Comment (by K-STOCK Editor)

This announcement updates the market regarding Hanwha Aerospace’s preliminary consolidated operating results for Q4 2025 and the full fiscal year. The critical variables that investors must monitor going forward are the ‘potential modifications to financial metrics during the external audit’ and the ‘official verification of final figures’ as explicitly outlined in the text.

As specified in the source filing, the reported figures remain unratified preliminary outcomes that may deviate from the final audited results. Given the documented parameters where annual revenue and operating profit increased while annual net income and controlling interest net profit decreased, investors should treat these preliminary allocations cautiously and focus strictly on tracking how these specific line items are finalized in the upcoming formal audit report.

📢 Disclaimer and Source Information

Source: This content has been structured and newly written based on the official data submitted to the Financial Supervisory Service Electronic Disclosure System (DART).

Investment Risk Notice: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: For inquiries regarding compliance or copyright requests, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Defense

Post navigation

Previous Post: [Disclosure] Hanwha Ocean (042660) Secures KRW 768.7B Contract from Affiliate Ocean Wind Power 1 Ltd. to Construct One Wind Turbine Installation Vessel
Next Post: [Disclosure] Hanwha Aerospace (012450) Reports FY2025 Consolidated Revenue Reaches KRW 26.6T, Jumping 136.7% YoY via Shipbuilding Sector Consolidation

Related Posts

[Disclosure] Hanwha Ocean (042660) Signs KRW 1.24T ‘4 LNG Carriers’ Construction Contract with Asian Shipowner Disclosures
[Disclosure] Celltrion (068270) Secures US FDA Final Marketing Authorization for ‘Stelara Biosimilar (CT-P43)’ Steqeyma Disclosures
[Disclosure] Celltrion (068270) Secures Final FDA Approval for ‘Omlyclo’, a Biosimilar of Xolair Disclosures
[Disclosure] Celltrion (068270), Unveils Mid-to-Long Term Strategy: Targets KRW 5T Revenue by 2025 and Evaluates CDMO Subsidiary Setup Disclosures
[Disclosure] Samsung Electronics (005930) Approves 2.45T KRW Quarterly Cash Dividend; Payout Fixed at 361 KRW per Share Semiconductors
[Disclosure] Hanwha Ocean (042660), Loan Expiry Date for KRW 234.2B to Singapore Subsidiary Extended to January 27, 2025 Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Alteogen (196170) Establishes August 6 as Record Date for Bonus Issue Share AllotmentJuly 16, 2026
  • [Disclosure] Alteogen (196170) Announces Trading Suspension and Resumption Schedule for Stock Futures and OptionsJuly 16, 2026
  • [Disclosure] Alteogen (196170) Temporarily Suspends Plans for Relisting on the KOSPI MarketJuly 16, 2026
  • [Disclosure] Alteogen (196170) Announces Temporary Trading Suspension on July 16 Due to Bonus Issue DecisionJuly 16, 2026
  • [Disclosure] Alteogen (196170) Decides on Bonus Issue of 0.3 Shares per 1 Common and Preferred ShareJuly 16, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme